Jewels that may help explain behavioral disorders found among
'junk' DNA
Scientists have been looking for genes that can explain behavioral disorders
for 20 years without much success. According to L. Alison McInnes of Mt. Sinai
School of Medicine, that may be because they have been concentrating their
efforts in the wrong places in the genome.
Speaking on Dec. 8 at the annual meeting of the American College of
Neuropsychopharmacology held in San Juan, Puerto Rico, McInnes advised that
those interested in genetic links to behavior should start looking at places in
the genome that produce special molecules called small non-messenger RNA (smnRNA)
rather than concentrating on genes that code for proteins.
Current genetic screening techniques do not pick up these sequences because
they are very small and not much is known about their structure. So McInnes and
her colleagues at Mt. Sinai have created a computational and molecular screening
technique designed specifically to look for smnRNA molecules produced by regions
in the genome that have been associated with behavioral disorders. Furthermore,
they have used this method to successfully identify such molecules in the first
few genes that they investigated, she reported.
The existence of smnRNAs has been known for some time. Until recently, they
have been generally dismissed as unimportant. New studies are finding that they
are actually quite abundant and involved in a wide variety of biological
processes. As a result, some scientists are beginning to speculate that they may
represent an entirely new class of gene and type of gene activity.
McInnes cited the theoretical work of John Mattick and Michael Gagen at the
University of Queensland in Brisbane. Last year they published a lengthy paper
in Molecular Biology and Evolution in which they argued that, rather than being
useless, smnRNAs and introns the sequences in the genome between genes that
code for proteins that have been called junk DNA form a powerful network that
can turn ordinary genes on and off at the proper times.
"It appears that smnRNA may be especially relevant for understanding
behavioral differences," McInnes said, "because they appear to be particularly
enriched in the brain. They represent a swift and energy efficient means of
regulating gene expression and may be especially important for rapid regulatory
events."
Lack of expression of an smnRNA has already been strongly associated with one
neuropsychiatric disorder, Prader Willi syndrome, McInnes reported. Prader-Willi
syndrome is characterized by abnormally poor muscle tone and feeding
difficulties in early infancy, followed by excessive eating and gradual
development of morbid obesity. It is also accompanied by cognitive impairment.
In the initial trial of their new screen, the Mt. Sinai researchers
identified a possible smnRNA molecule produced by an intron of the human
corticotrophin-releasing hormone gene. Corticotrophin releasing hormone (CRH)
plays a key role in the response of humans and other mammals to external
threats. It acts at a number of sites in the nervous system to control
automatic, behavioral and immunological responses of stress. Alterations in CRH
neural activity appear to contribute to a number of mental illnesses including
depression, anxiety disorders and anorexia nervosa. In addition, the CRH smnRNA
appears to form a complimentary match with a sequence in an untranslated region
associated with a receptor, called the NMDA-glutamate receptor, which is widely
implicated in schizophrenia and other degenerative neurological disorders.
The members of McInnes' research team are Esther Richler, Tara L. Lauriat,
Eric Mesh and Gary Benson from the biomathematics department. Former team member
Michael Inman also contributed to the research. The team also acknowledges the
valuable input of Jerome Cavaille, a pioneer in the discovery of snmRNA
molecules. The project was supported by the Seaver Center for Autism Research.
###
The American College of Neuropsychopharmacology (ACNP) is a professional
organization of some 600 leading scientists that was founded in 1961. Members
are selected primarily on the basis of their original research contributions to
the field of neuropsychopharmacology, which involves the evaluation of the
effects of natural and synthetic compounds on the brain, mind and human
behavior. The principal functions of the College are research and education.
ACNP's annual meeting is limited to participants from around the world who have
made major research or clinical contributions in the field.
ALL INFORMATION, DATA, AND
MATERIAL CONTAINED, PRESENTED, OR PROVIDED HERE IS FOR GENERAL INFORMATION
PURPOSES ONLY AND IS NOT TO BE CONSTRUED AS REFLECTING THE KNOWLEDGE OR OPINIONS
OF THE PUBLISHER, AND IS NOT TO BE CONSTRUED OR INTENDED AS PROVIDING MEDICAL OR
LEGAL ADVICE. THE DECISION WHETHER OR NOT TO VACCINATE IS AN IMPORTANT AND
COMPLEX ISSUE AND SHOULD BE MADE BY YOU, AND YOU ALONE, IN CONSULTATION WITH
YOUR HEALTH CARE PROVIDER.
"A foolish faith in authority is the worst enemy of truth."
-- Albert Einstein, letter to a friend, 1901
"I know of no safe depository of the ultimate powers of the society but the people themselves, and if we think them not enlightened enough to exercise control with a wholesome discretion, the remedy is not to take it from them, but to inform their discretion by education."
-- Thomas Jefferson, letter to William C. Jarvis, September 28, 1820
"What's the point of vaccination if it doesn't protect you from the unvaccinated?"
-- Sandy Gottstein
"Who gets to decide what the greater good is and how many will be sacrificed to it?"